NCT02552953: A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers

NCT02552953
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older(Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previously untreated CNS metastasis or progressive CNS metastasis
https://ClinicalTrials.gov/show/NCT02552953

Comments are closed.

Up ↑